logo
Plus   Neg
Share
Email

Medtronic Launches ADAPT-PD Trial In Parkinson's Disease Patients - Quick Facts

Medical technology company Medtronic plc (MDT) announced Thursday the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease (PD).

Adaptive deep brain stimulation is an investigational feature of the Percept PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson's disease based on a patient's clinical state.

The randomized study will take place across 12 study sites at leading Movement Disorders research centers in the United States, Europe, and Canada, with an estimated 36 subjects undergoing a total evaluation period of 15 months.

The primary endpoint of ADAPT-PD will compare standard continuous DBS (cDBS) to aDBS for hours of 'On' time without troublesome dyskinesias, a measure of treatment efficacy versus side effects, as reported by patient diary.

DBS therapy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver electrical stimulation to precisely targeted areas of the brain as adjunctive treatment for several neurological disorders.

Medtronic DBS systems were the first approved for full-body MRI scans under specific conditions in the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory... Hu Products has recalled a single production lot of the Hu Chocolate Covered Hunks - Sour Goldenberries Product citing the possible presence of undeclared almonds, an allergen, the U.S. Food and Drug Administration said. The recall involves 4 oz. bags of the Hu Chocolate Covered Hunks - Sour Goldenberries with UPC code of 850180006510, Best By Date of 08/2021, and Lot Code of 202891.
Follow RTT